Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Lovely Meds, Inc. dba Lovely Meds
WARNING LETTER
•Lovely Meds, Inc. dba Lovely Meds•August 31, 2025

Lovely Meds, Inc. dba Lovely Meds – FDA Warning Letter, Aug 31, 2025

Record Details

**FDA Warning Letter Summary**

**Company:** Lovely Meds **Inspection Dates:** August 2025 **Main Violations/Issues:** The FDA reviewed Lovely Meds" website and found that it offers compounded drug products, specifically semaglutide and tirzepatide, with claims that are false or misleading. The website suggests these compounded products have the same active ingredients as FDA-approved drugs like Wegovy, Ozempic, Zepbound, and Mounjaro. Such claims misbrand the products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA), as they imply equivalence to FDA-approved drugs, which compounded products are not. This misbranding results in the illegal introduction of these products into interstate commerce, violating section 301(a) of the FDCA.

**Regulatory Framework:** The violations are assessed under sections 502(a), 502(bb), and 301(a) of the FDCA [21 U.S.C. §§ 352(a), 352(bb), and 331(a)]. Misbranding is defined as false or misleading labeling or advertising of drug products.

**Required Actions:** Lovely Meds must immediately address these violations by ceasing the use of misleading language on their website. They are required to provide a written response within 15 working days to the Office of Compounding Quality and Compliance (OCQC) detailing the corrective actions taken. This response should include documentation of steps to prevent future violations. Failure to comply may result in legal actions, including product seizure and injunctions. If Lovely Meds believes their products are not in violation, they must provide supporting information. Correspondence should clearly reference the Warning Letter.

Company
Lovely Meds, Inc. dba Lovely Meds
Inspection date
August 31, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • George Tidmarsh (Director)
View Company Profile

ID · ea900d92-647a-4306-8ce1-8541e3ff27ee

Violation Codes8
FD&C Act 502(a)FD&C Act 502(b)21 U.S.C. 352(a)21 U.S.C. 352(bb)FD&C Act 301(a)FD&C Act 301(c)21 U.S.C. 331(c)21 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Other documents for Lovely Meds, Inc. dba Lovely Meds
  • WARNING_LETTER - 2025-08-01August 1, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Lovely Meds, Inc. dba Lovely Meds
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.